Endogenous antioxidants predicted outcome and increased after treatment: A benzoate dose-finding, randomized, double-blind, placebo-controlled trial for Alzheimer's disease.

Psychiatry Clin Neurosci · 2023 · PMC10099492 · PMID 36335573

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

showed a trendP = 0.10so close (0.05 < p ≤ 0.1)

Regarding the dose difference among the male patients, the benzoate 1000 group, but not the other two benzoate groups, showed a trend (insignificant) improvement in the ADAS‐cog performance than the placebo group at week 24 ( P = 0.10) and endpoint ( P = 0.11) (not shown).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.